Seroatlas · Human Serome Atlas

TGFBR2

TGF-beta receptor type-2

Also known as: MFS2, TBR-ii, TBRII, TGFR2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P37173
Gene
TGFBR2
Ensembl
ENSG00000163513
Chromosome
3
Canonical length
567 aa
Protein class
Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins
Subcellular location
Plasma membrane
Secretome location
Secreted to blood
Quaternary structure
Homodimer

OverviewNCBI Gene

The protein encoded by this gene is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with TGF-beta receptor type-1, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of genes related to cell proliferation, cell cycle arrest, wound healing, immunosuppression, and tumorigenesis. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized. [provided by RefSeq, Aug 2017]

Canonical amino-acid sequenceUniProt

567 residues, UniProt reviewed canonical sequence.

>P37173|TGFBR2
     1  MGRGLLRGLW PLHIVLWTRI ASTIPPHVQK SVNNDMIVTD NNGAVKFPQL CKFCDVRFST
    61  CDNQKSCMSN CSITSICEKP QEVCVAVWRK NDENITLETV CHDPKLPYHD FILEDAASPK
   121  CIMKEKKKPG ETFFMCSCSS DECNDNIIFS EEYNTSNPDL LLVIFQVTGI SLLPPLGVAI
   181  SVIIIFYCYR VNRQQKLSST WETGKTRKLM EFSEHCAIIL EDDRSDISST CANNINHNTE
   241  LLPIELDTLV GKGRFAEVYK AKLKQNTSEQ FETVAVKIFP YEEYASWKTE KDIFSDINLK
   301  HENILQFLTA EERKTELGKQ YWLITAFHAK GNLQEYLTRH VISWEDLRKL GSSLARGIAH
   361  LHSDHTPCGR PKMPIVHRDL KSSNILVKND LTCCLCDFGL SLRLDPTLSV DDLANSGQVG
   421  TARYMAPEVL ESRMNLENVE SFKQTDVYSM ALVLWEMTSR CNAVGEVKDY EPPFGSKVRE
   481  HPCVESMKDN VLRDRGRPEI PSFWLNHQGI QMVCETLTEC WDHDPEARLT AQCVAERFSE
   541  LEHLDRLSGR SCSEEKIPED GSLNTTK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TGFBR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.36
Highest tissue expression
216 nTPM

Expression across tissuesHPA

Tissue

  • adipose tissue: 216 nTPM
  • lung: 140 nTPM
  • breast: 126 nTPM
  • blood vessel: 112 nTPM
  • spleen: 105 nTPM
  • smooth muscle: 100 nTPM

Single-cell type

  • lymphatic endothelial cells: 890 nCPM
  • vascular endothelial cells: 806 nCPM
  • neutrophils: 767 nCPM
  • choroid plexus epithelial cells: 582 nCPM
  • microglia: 559 nCPM
  • pdcs: 463 nCPM

Immune cell

  • naive CD4 T-cell: 17 nTPM
  • neutrophil: 13 nTPM
  • eosinophil: 12 nTPM
  • basophil: 9.1 nTPM
  • non-classical monocyte: 8 nTPM
  • naive CD8 T-cell: 7.4 nTPM

Brain region

  • choroid plexus: 57 nTPM
  • thalamus: 38 nTPM
  • medulla oblongata: 29 nTPM
  • spinal cord: 28 nTPM
  • white matter: 27 nTPM
  • midbrain: 27 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TGFBR2.

Disease | AllUniProt

Conditions TGFBR2 is implicated in, by any mechanism.

Disease | GeneticClinVar

130 pathogenic / likely-pathogenic of 1,381 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.52
gnomAD pLI
0.13
gnomAD missense Z
2.24
DepMap mean gene effect
0.01
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TGFBR2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TGFBR2 as an antibody target. Whether an autoantibody or antibody against TGFBR2 could matter depends on whether native TGFBR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TGFBR2 is annotated at the cell surface, where native TGFBR2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TGFBR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TGFBR2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...